Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis. J of Skin. 2017;1(3.1):s10. doi:10.25251/skin.1.supp.9